Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial

Neurology

Volumn 49, Issue 2, 1997, Pages 351-357

  Van Oosten, B W ^a   Lai, M ^b   Hodgkinson, S ^c   Barkhof, F ^a   Miller, D H ^b   Moseley, I F ^b   Thompson, A J ^b   Rudge, P ^b   McDougall, A ^c   McLeod, J G ^c   Ader H J ^d   Polman, C H ^a,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CM T 412; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; T LYMPHOCYTE;

EID: 0030880011     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.351     Document Type: Article

References (30)

1. ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994;343:271-275.
2. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T-cell subsets within active chronic lesions. Science 1982;219:308-310.
3. Traugott U. Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J Neuroimmunol 1987;16:283-302.
4. Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL. Dual label immunocytochemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens. Ann Neurol 1988;24:523-531.
5. Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1 + 2-lymphocytes. J Immunol 1981;127:1420-1423.
6. Holda JH, Swanborg RH. Autoimmune effector cells II. Transfer of experimental allergic encephalomyelitis with a subset of T lymphocytes. Eur J Immunol 1982;12:453-455.
7. Mokhtarian F, McFarlin DE, Raine CS. Adoptive transfer of myelin basic protein sensitised T cells produces chronic replasing demyelinating disease in mice. Nature 1984;309:356-358.
8. Brostoff SW, Mason DW. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognized T helper cells. J Immunol 1984;133:1938-1942.
9. Waldor MK, Sriram S, Hardy R, et al. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T cell subset marker. Science 1985;227:415-417.
10. O'Neill JK, Baker D, Davison AN, et al. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J Neuroimmunol 1993;45:1-14.
11. Hodgkinson S, Lindsey JW, Allegretta M, et al. Phase I study of chimeric anti-CD4 monoclonal antibody in multiple sclerosis. Neurology 1992;42(suppl 3):209.
12. Lindsey JW, Hodgkinson S, Mehta R, et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994;44:413-419.
13. Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 1994;36:183-189.
14. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555.
15. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
16. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
17. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094.
18. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994;122:6-14.
19. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
20. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
21. van Oosten BW, Lai M, Barkhof F, et al. A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Multiple Sclerosis 1996;1:339-342.
22. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
24. Dalesandro MR, Pak KY, Tam S, et al. Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 antibody. Int Immunol 1993;5:283-291.
25. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
26. Rumbach L, Racadot E, Bataillard M, et al. Essai thérapeutique ouvert d'un anticorps monoclonal anti-T CD4 dans la sclérose en plaques. Rev Neurol (Paris) 1994;150:418-424.
27. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237.
28. Chace JH, Cowdery JS, Field EH. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol 1994;152: 404-412.
29. Llewellyn-Smith N, Lai M, Miller DH, Rudge P, Thompson AJ, Cuzner ML. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology 1997;48:810-816.
30. Rep MHG, van Oosten BW, Roos MTL, Adèr HJ, Polman CH, van Lier RAW. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-γ secreting TH1 cells in humans. J Clin Invest 1997;99:2225-2231.